Cinclus Pharma
12.24 SEK
+0.66 %
Less than 1K followers
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+0.66 %
-27.06 %
-29.33 %
-36.45 %
-30.45 %
+22.40 %
-
-
-62.46 %
Cinclus Pharma is a Swedish clinical-stage pharmaceutical company. The company is active in the development of molecules for the treatment of acid-related diseases. The company's lead drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
580.08M SEK
Turnover
639.35K SEK
Revenue
57.47M
EBIT %
-347.24 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
21.5
2026
General meeting '26
19.8
2026
Interim report Q2'26
11.11
2026
Interim report Q3'26
All
Webcasts
Press releases
ShowingAll content types
Cinclus Pharma, Audiocast, Q1'26
Interim report January-March 2026 - Phase III study approaching full enrollment
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
